Literature DB >> 23708511

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients.

Alberto M Martelli, Annalisa Lonetti, Sergio Amadori, James A McCubrey, Francesca Chiarini.   

Abstract

Entities:  

Keywords:  PI3K/Akt/mTOR; apoptosis; autophagy; cell cycle; combination therapy; leukemia initiating cells; targeted therapy; translation

Mesh：

Substances：

Year:  2013        PMID： 23708511      PMCID： PMC3735688          DOI： 10.4161/cc.25117

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  8 in total

1.  A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

Authors:  S Park; N Chapuis; F Saint Marcoux; C Recher; T Prebet; P Chevallier; J-Y Cahn; T Leguay; P Bories; F Witz; T Lamy; P Mayeux; C Lacombe; C Demur; J Tamburini; A Merlat; R Delepine; N Vey; F Dreyfus; M C Béné; N Ifrah; D Bouscary
Journal:  Leukemia       Date:  2013-01-16       Impact factor: 11.528

2.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

Authors:  Graça M Dores; Susan S Devesa; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Blood       Date:  2011-11-15       Impact factor: 22.113

3.  Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).

Authors:  Sergio Amadori; Roberto Stasi; Alberto M Martelli; Adriano Venditti; Giovanna Meloni; Fabrizio Pane; Giovanni Martinelli; Monia Lunghi; Livio Pagano; Daniela Cilloni; Elena Rossetti; Francesco Di Raimondo; Claudio Fozza; Luciana Annino; Francesca Chiarini; Francesca Ricci; Emanuele Ammatuna; Edoardo La Sala; Paola Fazi; Marco Vignetti
Journal:  Br J Haematol       Date:  2011-11-15       Impact factor: 6.998

Review 4.  Leukemia stem cells.

Authors:  Eike C Buss; Anthony D Ho
Journal:  Int J Cancer       Date:  2011-09-14       Impact factor: 7.396

5.  A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Authors:  Alexander E Perl; Margaret T Kasner; Donald E Tsai; Dan T Vogl; Alison W Loren; Stephen J Schuster; David L Porter; Edward A Stadtmauer; Steven C Goldstein; Noelle V Frey; Sunita D Nasta; Elizabeth O Hexner; Jamil K Dierov; Cezary R Swider; Adam Bagg; Alan M Gewirtz; Martin Carroll; Selina M Luger
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

Review 6.  The role of clofarabine in acute myeloid leukemia.

Authors:  Hady Ghanem; Hagop Kantarjian; Maro Ohanian; Elias Jabbour
Journal:  Leuk Lymphoma       Date:  2012-09-28

7.  A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Authors:  Francesca Chiarini; Annalisa Lonetti; Gabriella Teti; Ester Orsini; Daniela Bressanin; Alessandra Cappellini; Francesca Ricci; Pier Luigi Tazzari; Andrea Ognibene; Mirella Falconi; Pasqualepaolo Pagliaro; Ilaria Iacobucci; Giovanni Martinelli; Sergio Amadori; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-12

Review 8.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04
  8 in total
  3 in total

Review 1.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

2.  Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways.

Authors:  Hongfei Wang; Yongqiang Wang; Hongmei Gao; Bing Wang; Lin Dou; Yin Li
Journal:  Oncol Lett       Date:  2017-11-29       Impact factor: 2.967

3.  Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Authors:  Stephen L Abrams; Peter P Ruvolo; Vivian R Ruvolo; Giovanni Ligresti; Alberto M Martelli; Lucio Cocco; Stefano Ratti; Agostino Tafuri; Linda S Steelman; Saverio Candido; Massimo Libra; James A McCubrey
Journal:  Oncotarget       Date:  2017-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.